Elevating Drug Development. Every Step of the Way
About Scinai Immunotherapeutics
nasdaq: scni
Scinai is a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bio-services business unit.
Top-tier pharma leadership team
Record of success in biotech start-ups and pharma multi-nationationals
Amir Reichman
CEO
Tamar Ben Yedidia
CSO
Elad Mark
COO
Dalit Fischer
CTO
Inflammatory & IMMUNOLOGY Therapeutics Pipeline
Scinai is focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.
Our Alpaca-derived nanosized antibodies (nanoAbs), also known as VHH-antibodies, address diseases with large unmet medical needs and attractive commercial opportunities, such as psoriasis and asthma.
Diverse drug platform
Proven target molecules & mechanism of action
Addressing large markets with unmet needs
Saving costs & improving patient compliance
DEVELOPED IN collaboration with WORLD LEADERS IN NANOAB discovery & OPTIMIZATION
Scinai’s NanoAbs are developed in collaboration with the world-renowned Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen, Germany. Our scientific partners are leaders in designing and optimizing NanoAbs.
Professor Dr. Dirk Görlich
Professor & Director at Max Planck Institute for Multidisciplinary Sciences
2024 Louis-Jeantet Prize & 2022 WLA Prize
Professor Dr. Matthias Dobbelstein
Max Planck Institute Fellow, Professor and Department Head at the University of Göttingen
Scinai CDMO Bio-Services
Supporting pharmaceutical, and biotech companies every step of the way through their drug development process and manufacturing for nonclinical and clinical studies. We offer cost-effective, agile, and scalable boutique services that combine innovation and process excellence, from development and manufacturing to product delivery.
Process development & Scale-up
-
Clone selection
Upstream – fermentation process for bacteria yeast and fungi
Downstream purification
Process optimization
Process scale-up
Analytical Methods Development
-
State-of the art analytical methods for in-process control, release testing, and characterization of recombinant proteins.
In-house expertise to characterize, monitor and optimize your product’s quality attributes across all stages of development.
cGMP Manufacturing
-
Upstream fermentation up to 300L
Downstream purification
Media and buffer preparation
Aseptic filling of vials and PFS
Visual inspection
QA and QC protocols to ensure highest regulatory and safety standards
Quality management system
our expertise
As a biopharmaceutical manufacturer with over 20 years of experience in recombinant protein process development and cGMP manufacturing, Scinai offers:
A wide-ranging top-tier pharma & biotech expertise
Ability to rapidly execute multiple projects, while ensuring full process and product compliance at all stages.
State-of-the-art development and manufacturing facility in Israel, meeting EMA and FDA GMP standards.
*AYANA
* neurogenesis
* voyager medical research
* Mileutis
*AYANA * neurogenesis * voyager medical research * Mileutis
Trusted by…
-
![]()
ayana pharma
“We selected Scinai due to their vast experience in bio-pharmaceutical drug development and manufacturing for clinical trials while meeting stringent international regulatory requirements. The pristine condition of Scinai’s modern and highly equipped laboratories and clean rooms demonstrate the competence and attention to detail that are imperative for a CDMO to successfully serve our future needs.”
Yanir Aldouby, COO -
![]()
VOYAGER MEDICAL RESEARCH
״We were looking for a professional partner for the ongoing development and production of our product. Scinai was exactly what we were looking for in a partner. We found their team to be professional, reliable, and particularly attentive to our needs, demonstrating the flexibility we needed.״
Ohad Lavi, CEO -
![]()
NeuroGenesis
״Scinai provided us with professional advice and support at the start of our journey. We received timely professional responses, with thoughtful attention to our requests.״
Nir Netzer, COO
What’s New?
Information Resources
-
![]()
ONLINE EXPERT PANEL
Plaque Psoriasis- The Unmet Need and and Intralesional Injections of anti-IL-17A/F VHH Antibodies as a potential solution.
-
![]()
ELEVATING DRUG DEVELOPMENT
Scinai’s NanoAb innovation was featured in a presentation at the recent 5th Annual Dermatology Drug Development Summit in Berlin.
-
![]()
Scinai analyst & investors webinar
CEO Amir Reichman reviews the company’s performance in 2023, and updates on new clinical study results and financial developments.
-
![]()
COLLABORATION WITH THE EIB
Scinai’s financial strategy enhanced in collaboration with the European Investment Bank, converting loan to equity.
-
![]()
Scinai Nanobody technology demonstrates efficacy in neutralizing COVID
Our innovative nanobody technology has shown remarkable efficacy in neutralizing multiple SARS-CoV-2 variants in an article published by the Antiviral Research journal.
Contact us
Get in touch to explore partnership opportunities and consult our CDMO specialists